EPM
SMMT icon

Equitec Proprietary Markets’s Summit Therapeutics SMMT Stock Holding History

Equitec Proprietary Markets’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,200
Closed -$12.6K – 137
2023
Q1 		$12.6K Buy
+7,200
New +$19.6K 0.01% 86

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Equitec Proprietary Markets's SMMT Position: Q2 2023 in Review

Equitec Proprietary Markets sold out of Summit Therapeutics (SMMT) in Q2 2023, closing a stake of 7,200 shares — an estimated $12.6K sold.

Equitec Proprietary Markets first reported a position in SMMT in Q1 2023 and held it in 1 quarter. The position peaked at $12.6K in Q1 2023. 100 funds tracked by Wall St. Rank hold SMMT as of Q2 2023.

  • Equitec Proprietary Markets reported no remaining Summit Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Equitec Proprietary Markets sold 7,200 Summit Therapeutics shares in Q2 2023, an estimated $12.6K.
  • Equitec Proprietary Markets first reported a position in Summit Therapeutics in Q1 2023 and held it in 1 quarter.
  • Equitec Proprietary Markets's Summit Therapeutics position peaked at $12.6K in Q1 2023.
  • 100 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2023.

Based on Equitec Proprietary Markets's 13F filing for Q2 2023, filed 12 Jul 2023.